• SKIP TO CONTENT
  • SKIP NAVIGATION
  • Patient Resources
    • COVID-19 Patient Resource Center
    • Clinical Trials
    • Search Clinical Trials
    • Patient Notification System
    • What is Clinical Research?
    • Volunteering for a Clinical Trial
    • Understanding Informed Consent
    • Useful Resources
    • FDA Approved Drugs
  • Professional Resources
    • Research Center Profiles
    • Clinical Trial Listings
    • Market Research
    • FDA Approved Drugs
    • Training Guides
    • Books
    • eLearning
    • Events
    • Newsletters
    • JobWatch
    • White Papers
    • SOPs
    • eCFR and Guidances
  • White Papers
  • Trial Listings
  • Advertise
  • COVID-19
  • iConnect
  • Sign In
  • Create Account
  • Sign Out
  • My Account
Home » Cellular Biomedicine Group, Chinese PLA General Hospital ink agreement

Cellular Biomedicine Group, Chinese PLA General Hospital ink agreement

February 11, 2015
CenterWatch Staff

Cellular Biomedicine Group, a Palo Alto, Calif.-based biomedicine company engaged in the development of cellular therapies for degenerative and cancerous diseases, has acquired Chinese PLA General Hospital's (PLAGH, Beijing, also known as 301 Hospital) Chimeric Antigen Receptor T cell (CAR-T) therapy; its recombinant expression vector CD19, CD20, CD30 and Human Epidermal Growth Factor Receptor's (EGFR or HER1) Immuno-Oncology patents (all pending); and phase I/II clinical data of the aforementioned therapies and manufacturing knowledge.

CAR-T cell therapy involves engineering cancer patients' own immune cells to recognize and attack their tumors. Wei Dong Han, M.D., Ph.D., head of PLAGH's biotherapy department, has conducted several preliminary clinical studies of various CAR-T constructs targeting CD19-positive acute lymphoblastic leukemia, CD20-positive lymphoma, CD30-positive Hodgkin's lymphoma and EGFR-HER1-positive advanced lung cancer. The hospital consists of 125 clinical, medical and technological departments and 4,000 patient beds, with annual volumes of approximately four million patients and more than 65,000 surgeries.

Prior to acquiring PLAGH's technology, the company has made progress with recent acquisitions of Agreen Biotech and its T-Cell Memory technology (Tcm), T Cell Receptor clonality analysis technology, as well as another third generation CAR-T, anti-PD-1, CD19 and aAPC cancer immunotherapy technologies from Persongen Biotechnology. Together with PLAGH's technology, Cellular Biomedicine Group's state-of-the art infrastructure and clinical platform, along with these acquired technologies, will enable improvement of cancer immune cell therapies and strategic combination therapies, which will boost the company's Immuno-Oncology presence and pave the way for future partnerships.

"This is the beginning of a long-term strategic partnership between Cellular Biomedicine Group and PLAGH. Together, we will expeditiously continue our quest in developing safer and more effective cancer immunotherapy programs with leading hospitals and other partners," said Dr. William (Wei) Cao, CEO of Cellular Biomedicine Group.

Upcoming Events

  • 24May

    Powering an Effective Oversight Strategy with Clinical and Operational Insights

  • 25May

    2022 WCG Avoca Quality & Innovation Summit: Own the Future

  • 28Jun

    Effective Root Cause Analysis and CAPA Investigations for the Life Sciences

  • 16Oct

    WCG MAGI's Clinical Research Hybrid Conference - 2022 West

Featured Products

  • Spreadsheet Validation: Tools and Techniques to Make Data in Excel Compliant

    Spreadsheet Validation: Tools and Techniques to Make Data in Excel Compliant

  • Surviving an FDA GCP Inspection

    Surviving an FDA GCP Inspection: Resources for Investigators, Sponsors, CROs and IRBs

Featured Stories

  • Protocol-360x240.png

    Avoid Deviations by Making Protocol Review a Team Effort

  • SelectionProcess-360x240.png

    Give Us a Voice: Sites Clamor for a Say on Vendor Selection

  • Convince-360x240.png

    Use Data and Details to Convince Site Leadership to Add Staff

  • AsktheExpertsBadge-360x240.png

    Ask the Experts: Listing Trial Staff and Others on the Statement of Investigator

Standard Operating Procedures for Risk-Based Monitoring of Clinical Trials

The information you need to adapt your monitoring plan to changing times.

Learn More Here
  • About Us
  • Contact Us
  • Privacy Policy
  • Do Not Sell My Personal Information

Footer Logo

300 N. Washington St., Suite 200, Falls Church, VA 22046, USA

Phone 617.948.5100 – Toll free 866.219.3440

Copyright © 2022. All Rights Reserved. Design, CMS, Hosting & Web Development :: ePublishing